Browse by Audience
MEMBER

Update Your Profile
Member Spotlights
Refer a Member: IASP Champions
Join a Special Interest Group (SIG)
Find a Chapter
Join Now

RESEARCHER

PAIN
PAIN Reports
Pain Research Forum
Papers of the Week
Webinars and Podcasts
Events

HEALTH CARE PROVIDER

Online Learning - PERC
Webinars & Podcasts
Curricula
Graduate Opportunities
Events

PATIENT & CAREGIVER

RELIEF News
Resources for Living with Pain
Global Alliance of Partners in Pain Advocacy (GAPPA)
Events

PARTNER

Support IASP
Sponsor an Event
Become a Partner

gy2022-1-3
I am a
IASP Logo
Home I AM A Search Login

Papers of the Week

Home / Publications / Pain Research Forum / Papers of the Week / A CGRP receptor antagonist peptide formulated for nasal administration to treat migraine.

< BACK TO ARCHIVE


Papers: 27 Jun 2020 - 3 Jul 2020


Pharmacology/Drug Development

PAIN TYPE:
Migraine/Headache


2020 Jun 25


J Pharm Pharmacol


http://www.ncbi.nlm.nih.gov/pubmed/32588458?dopt=Abstract

A CGRP receptor antagonist peptide formulated for nasal administration to treat migraine.

Authors

A CGRP receptor antagonist peptide formulated for nasal administration to treat migraine.
von Mentzer B, Russo AF, Zhongming Z, Kuburas A, Killoran PM, D'Aloisio V, Nizic L, Capel V, Kendall DA, Coxon CR, Hutcheon GA
J Pharm Pharmacol. 2020 Jun 25.
PMID: 32588458.

Abstract

To investigate the formulation of the peptide-based antagonist ( Pro, Phe)CGRP , of the human calcitonin gene-related peptide (CGRP) receptor as a potential nasally delivered migraine treatment.
Read This Paper